Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Plant compound protects healthy cells from chemotherapy drugs

No. 16 | 07/04/2014 | by Zim/Küh

Chemotherapy drugs attack not only cancer cells but more generally rapidly dividing tissues. This can cause side effects ranging from hair loss to nausea to deadly infections. Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now discovered that the plant compound rocaglamide protects healthy cells from the toxic effects of chemotherapy drugs. This discovery may help reduce the side effects of cancer therapies.

The compound rocaglamide is extracted from plants of the Aglaia species.Picture: Nguyễn Thanh Quang, Wikimedia Commons

Most chemotherapy drugs damage the DNA of dividing cells. These include not only cancer cells but also healthy cells such as blood, hair follicles, and cells of the mucous membranes of the stomach and gut. So far, researchers have identified only a few drugs that can directly prevent such adverse side effects on healthy tissues, but it has been unclear whether some of these drugs also protect cancer cells themselves from the effects of chemotherapy. This motivated Dr. Min Li-Weber and her team at the DKFZ to search for new compounds. "Rocaglamide was one of many plant substances that we examined," said study head Li-Weber. "This substance is extracted from herbs and has been used in Chinese medicine for many years as, for example, an anti-inflammatory agent."

To determine whether rocaglamide protects healthy cells from chemotherapy drugs, the researchers treated white blood cells from healthy donors with various chemotherapy drugs while adding various levels of rocaglamide. The result: "The more rocaglamide we used, the more white blood cells survived," reports Li-Weber. By contrast, the substance did not have any impact on the survival rate of the cancer cell lines used in the experiment.

How exactly does rocaglamide work? Could it somehow prevent DNA damage in healthy cells? To pursue these questions, the scientists compared the state of DNA in cells either with or without rocaglamide after adding a chemotherapy drug. "The damage was almost identical," says Michael Becker, first author of the publication. "This means on the one hand that rocaglamide does not directly prevent the effects of chemotherapy drugs. On the other hand, it also means that the compound itself does not cause any DNA damage."

In further tests, the scientists found that rocaglamide inhibits the production of the protein p53. This protein, which is also called a "guardian of the genome," is produced by cells that have undergone DNA damage. When p53 reaches a certain level, it induces "programmed cell death,” making sure that the defective cell dies. "Rocaglamide prevents healthy cells that have had contact with a chemotherapy drug from producing the p53 protein and thus from activating programmed cell death," Becker explains. "Since p53 is absent or defective in the cancer cells of about half of all cancer types, rocaglamide had no impact on the cancer cells in our tests." Patients suffering from tumors that do not produce p53 may therefore benefit from rocaglamide, because in these cases, the substance protects only the healthy cells from the effects of chemotherapy.

However, what are the consequences if cells with damaged DNA do not die promptly? Could they give rise to new cancer cells? "Numerous experiments in other labs have shown that inhibiting p53 for a short time does not cause the cancer risk to rise," Becker reports. “Our next step is to determine whether this also holds true for rocaglamide." Becker already has a hypothesis, which remains to be tested, that might explain why p53 inhibitors do not increase a person’s risk of developing cancer: "They might give cells more time to repair damage to their DNA."

Becker MS, Schmezer P, Breuer R, Haas SF, Essers MA, Krammer PH, Li-Weber M. (2014) The traditional Chinese medical compound Rocaglamide protects nonmalignant primary cells from DNA damage-induced toxicity by inhibition of p53 expression. Cell Death Dis. doi: 10.1038/cddis.2013.528

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS